Adjuvant chemotherapy in the treatment of high grade gliomas

Sara Lonardi, Alicia Tosoni, Alba A. Brandes

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Standard treatment of high-grade glioma (HGG) is based on surgery followed by limited field radiotherapy, while the role of chemotherapy is still controversial. Many randomized trials addressing the role of post-radiation or "adjuvant" chemotherapy have been conducted in the last three decades, yielding negative or inconclusive results. A statistically significant survival benefit with adjuvant chemotherapy has been demonstrated in two meta-analyses. The estimated absolute increase in survival is modest (≤ 10% at 1 year) but significant, and it appears independent of age, Performance Status and histology. Nitrosourea-based regimens were long considered the standard chemotherapy options for HGG, but their toxicity is not negligible. Temozolomide (TMZ) is a promising new drug that seems to be effective in patients with recurrent disease. Clinically and statistically significant survival benefit with the administration of TMZ concomitant and after radiotherapy has been recently demonstrated, establishing a new standard in HGG adjuvant treatment. Randomized comparisons with nitrosoureas are lacking and represent a major issue to be studied in future phase III trials.

Original languageEnglish
Pages (from-to)79-89
Number of pages11
JournalCancer Treatment Reviews
Volume31
Issue number2
DOIs
Publication statusPublished - Apr 2005

Fingerprint

temozolomide
Adjuvant Chemotherapy
Glioma
Survival
Radiotherapy
Drug Therapy
Meta-Analysis
Histology
Therapeutics
Radiation
Pharmaceutical Preparations

Keywords

  • Adjuvant
  • Brain tumours
  • Chemotherapy
  • Clinical trials
  • Prognosis
  • Radiotherapy
  • Review
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Adjuvant chemotherapy in the treatment of high grade gliomas. / Lonardi, Sara; Tosoni, Alicia; Brandes, Alba A.

In: Cancer Treatment Reviews, Vol. 31, No. 2, 04.2005, p. 79-89.

Research output: Contribution to journalArticle

Lonardi, Sara ; Tosoni, Alicia ; Brandes, Alba A. / Adjuvant chemotherapy in the treatment of high grade gliomas. In: Cancer Treatment Reviews. 2005 ; Vol. 31, No. 2. pp. 79-89.
@article{e3b90af06059441cb1a929ea865465e2,
title = "Adjuvant chemotherapy in the treatment of high grade gliomas",
abstract = "Standard treatment of high-grade glioma (HGG) is based on surgery followed by limited field radiotherapy, while the role of chemotherapy is still controversial. Many randomized trials addressing the role of post-radiation or {"}adjuvant{"} chemotherapy have been conducted in the last three decades, yielding negative or inconclusive results. A statistically significant survival benefit with adjuvant chemotherapy has been demonstrated in two meta-analyses. The estimated absolute increase in survival is modest (≤ 10{\%} at 1 year) but significant, and it appears independent of age, Performance Status and histology. Nitrosourea-based regimens were long considered the standard chemotherapy options for HGG, but their toxicity is not negligible. Temozolomide (TMZ) is a promising new drug that seems to be effective in patients with recurrent disease. Clinically and statistically significant survival benefit with the administration of TMZ concomitant and after radiotherapy has been recently demonstrated, establishing a new standard in HGG adjuvant treatment. Randomized comparisons with nitrosoureas are lacking and represent a major issue to be studied in future phase III trials.",
keywords = "Adjuvant, Brain tumours, Chemotherapy, Clinical trials, Prognosis, Radiotherapy, Review, Survival",
author = "Sara Lonardi and Alicia Tosoni and Brandes, {Alba A.}",
year = "2005",
month = "4",
doi = "10.1016/j.ctrv.2004.12.005",
language = "English",
volume = "31",
pages = "79--89",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Adjuvant chemotherapy in the treatment of high grade gliomas

AU - Lonardi, Sara

AU - Tosoni, Alicia

AU - Brandes, Alba A.

PY - 2005/4

Y1 - 2005/4

N2 - Standard treatment of high-grade glioma (HGG) is based on surgery followed by limited field radiotherapy, while the role of chemotherapy is still controversial. Many randomized trials addressing the role of post-radiation or "adjuvant" chemotherapy have been conducted in the last three decades, yielding negative or inconclusive results. A statistically significant survival benefit with adjuvant chemotherapy has been demonstrated in two meta-analyses. The estimated absolute increase in survival is modest (≤ 10% at 1 year) but significant, and it appears independent of age, Performance Status and histology. Nitrosourea-based regimens were long considered the standard chemotherapy options for HGG, but their toxicity is not negligible. Temozolomide (TMZ) is a promising new drug that seems to be effective in patients with recurrent disease. Clinically and statistically significant survival benefit with the administration of TMZ concomitant and after radiotherapy has been recently demonstrated, establishing a new standard in HGG adjuvant treatment. Randomized comparisons with nitrosoureas are lacking and represent a major issue to be studied in future phase III trials.

AB - Standard treatment of high-grade glioma (HGG) is based on surgery followed by limited field radiotherapy, while the role of chemotherapy is still controversial. Many randomized trials addressing the role of post-radiation or "adjuvant" chemotherapy have been conducted in the last three decades, yielding negative or inconclusive results. A statistically significant survival benefit with adjuvant chemotherapy has been demonstrated in two meta-analyses. The estimated absolute increase in survival is modest (≤ 10% at 1 year) but significant, and it appears independent of age, Performance Status and histology. Nitrosourea-based regimens were long considered the standard chemotherapy options for HGG, but their toxicity is not negligible. Temozolomide (TMZ) is a promising new drug that seems to be effective in patients with recurrent disease. Clinically and statistically significant survival benefit with the administration of TMZ concomitant and after radiotherapy has been recently demonstrated, establishing a new standard in HGG adjuvant treatment. Randomized comparisons with nitrosoureas are lacking and represent a major issue to be studied in future phase III trials.

KW - Adjuvant

KW - Brain tumours

KW - Chemotherapy

KW - Clinical trials

KW - Prognosis

KW - Radiotherapy

KW - Review

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=17444402489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17444402489&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2004.12.005

DO - 10.1016/j.ctrv.2004.12.005

M3 - Article

VL - 31

SP - 79

EP - 89

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 2

ER -